6-thioguanine levels in pediatric IBD patients: Adherence is more important than dose

Inflammatory Bowel Diseases

Volumn 19, Issue 12, 2013, Pages 2652-2658

  LeLeiko, Neal S ^a,b   Lobato, Debra ^a,b   Hagin, Sarah ^a,b   Hayes, Christopher ^a,b   McQuaid, Elizabeth L ^a,b   Seifer, Ronald ^b,c,d   Kopel, Sheryl J ^a,b   Boergers, Julie ^a,b   Nassau, Jack ^a,b   Suorsa, Kristina ^a   Shapiro, Jason ^a,b   Bancroft, Barbara ^a  

^a HASBRO CHILDREN'S HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c Bradley Hasbro Children's Research Center   (United States)

^d E P BRADLEY HOSPITAL   (United States)

Author keywords

Electronic monitoring; Objective measures; Treatment effectiveness; Treatment efficacy

Indexed keywords

AMINOSALICYLIC ACID; MERCAPTOPURINE; TIOGUANINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; ENTERITIS; FEMALE; HUMAN; MALE; MEDICATION COMPLIANCE; PATIENT MONITORING; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ERYTHROCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEDICATION ADHERENCE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; THIOGUANINE; YOUNG ADULT;

EID: 84888322558     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000436960.00405.56     Document Type: Article

References (27)

1. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1124-1129.
2. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4:1118-1123.
3. Markowitz J, Rosa J, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology. 1990; 99:1347-1351. PubMed PMID: 1976562.
4. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902. PubMed PMID: 11040176.
5. Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and metaanalysis. Am J Gastroenterol. 2011;106:630-642. Epub 2011 Mar 15. Review. PubMed PMID: 21407186.
6. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-483. doi:10.1038/ajg.2008.168.
7. Kamperidis N, Goodhand JR, Chowdhury FA, et al. Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012;54:685-689.
8. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047-1053. PubMed PMID: 16618398.
9. Morales A, Salguti S, Miao CL, et al. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:380-385. PubMed PMID: 17206711.
10. Neurath MF, Kiesslich R, Teichgräber U, et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3: 1007-1014. PubMed PMID: 16234047.
11. Achkar JP, Stevens T, Easley K, et al. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:339-345. PubMed PMID: 15475740.
12. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology. 2002;122:904-915. PubMed PMID: 11910342.
13. Dubinsky MC, Lamothe S, Yang HY, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713. PubMed PMID: 10734022.
14. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol. 2004;99:1744-1748. PubMed PMID: 15330913.
15. Hindorf U, Lyrenäs E, Nilsson A, et al. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1105-1112. PubMed PMID: 15545169.
16. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989; 7:1816-1823. Erratum in: J Clin Oncol 1990 Mar;8:567. PubMed PMID: 2585022.
17. Hande S, Wilson-Rich N, Bousvaros A, et al. 5-Aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006;12:251-257.
18. LeLeiko NS, Martin BA, Walsh M, et al. Tissue-specific gene expression results from a purine- and pyrimidine-free diet and 6-mercaptopurine in the rat small intestine and colon. Gastroenterology. 1987;93:1014-1020. PubMed PMID: 3653629.
19. Oliva-Hemker MM, Abadom V, Cuffari C, et al. Nonadherence with thiopurine immunomodulator and mesalamine medications in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2007;44:180-184.
20. Hommel KA, Davis CM, Baldassano RN. Objective versus subjective assessment of oral medication adherence in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:589-593. doi: 10.1002/ibd.20798.
21. LeLeiko NS, Lobato D, Hagin S, et al. Rates and predictors of oral medication adherence in pediatric IBD patients. Inflamm Bowel Dis. 2013;19: 832-839. doi: 10.1097/MIB.0b013e3182802b57. PMID: 23446336.
22. Kappelman MD, Crandall WV, Colletti RB, et al. Short pediatric Crohn's disease activity index for quality improvement and observational research. Inflamm Bowel Dis. 2011;17:112-117.
23. Turner D, Griffiths AM, Walters TD, et al. Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 2012;18:55-62.
24. Shepanski MA, Markowitz JE, Mamula P, et al. Is an abbreviated Pediatric Crohn's Disease Activity Index better than the original? J Pediatr Gastroenterol Nutr. 2004;39:68-72.
25. Farley J, Hines S, Musk A, et al. Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self report, and appointment keeping. J Acquir Immune Defic Syndr. 2003;33:211-218.
26. Gerson AC, Furth SL, Neu AM, et al. Assessing associations between medication adherence and potentially modifiable psychosocial variables in pediatric kidney transplant recipients and their families. Pediatr Transplant. 2004;8:543-550.
27. Martin S, Elliott-DeSorbo DK, Wolters PL, et al. Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents. Pediatr Infect Dis J. 2007;26:61-67.